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Obesity in Pregnancy : Consequences, Management, and
Potential Amelioration
The majority of adults in the United States are over-
weight or obese and the prevalence of obesity has
increased dramatically over the past few decades. In one
recent report (Am J ObGynec 2001; 185:845), the percent-
age of pregnant women with a body mass index greater
than 29 kg/m2 increased from 16% to 36% from 1980 to
2000. Although in the past various weight cutoffs were
used to define obesity, currently the body mass index is
usually chosen. It is determined by dividing the weight
of a woman in kilograms by her height in meters
squared. The advantage of the BMI over using an
individual’s weight alone is to distinguish the tall
woman who is not fat from the short woman who is.
Body mass categories for the start of pregnancy are in-
dicated in the table, as are the Institute of Medicine
recommendations for weight gain during pregnancy. A
BMI greater than 29 defines obesity. This BMI is achieved
by a weight more than 147 pounds for a woman 5 feet
tall and more than 191 pounds for a woman 5 feet 8
inches tall. Morbid or extreme obesity is often defined
as a BMI greater or equal to 40.
low birth weight (less than 2500 g or less than 5-1/2
pounds) were at increased risk for neonatal mortality
and morbidity. This public health interest in minimiz-
ing the rate of low birth weight infant delivery by
liberalizing weight gain recommendations for the preg-
nant woman may have had unintended adverse
consequences, but more about that later.
Are there increased risks of obesity on
pregnancy outcome?
There certainly are. Studies which look at the rela-
tionship between obesity and pregnancy outcomes are
retrospective comparisons. Some are from individual
institutions where small numbers preclude identifying
an association between obesity and very infrequent oc-
currences; others are from large databases raising
questions as to the validity of the entered data. None-
theless, the results of most studies are uniform
concerning many risks and complications. The relative
risks that the obese pregnant woman faces compared
with her non-obese counterpart depend on how con-
trolled the studies are for confounding variables (e.g.,
advanced age, low socioeconomic status). Studies are
uniform or nearly so regarding the following complica-
tions:
• Diabetes mellitus (mostly gestational, but also
insulin dependent).
• Hypertension (both chronic and preeclampsia).
• Labor induction.
• Dystocia in labor.
• Cesarean delivery (and decreased likelihood of
VBAC success).
• Fetal macrosomia.
• Shoulder dystocia.
• Wound complications.
• Possible increased risk of fetal neural tube
defects (studies vary).
• Possible increased risk of fetal death (overall, the
risk is increased, but it is unclear whether this is
true, independent of hypertension and diabetes).
Institute of Medicine Recommendations for
Weight Gain in Pregnancy
(National Academy Press; 1990; Washington D.C.)
IOM Recommended
Initial Body Mass Index Gestational Weight Gain
lb/kg
<19.8 (low) 28-40 / 12.5-18
19.8-26.0 (normal) 25-35 / 11.5-16
26.1-29.0 (high) 15-25 / 7-11.5
>29.0 (obese) at least 15/at least 6
The goal of the Institute of Medicine weight gain rec-
ommendations was to minimize the rate of low birth
weight infant delivery. It was recognized that infants of
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Management
Obesity increases the difficulty of providing obstet-
ric care. It is well recognized that surgery is more
difficult in the obese patient, but many other aspects of
care are as well. Clinically estimating fetal weight or
presentation, institution of anesthesia, obtaining intra-
venous access, and ultrasound examinations are all
much more difficult in the obese woman. In my view in
the presence of obesity, routine care should be modi-
fied as follows:
1. Dietary advice/weight gain recommendation.
Suggest that the patient eat well-balanced meals to
appetite. Although the Institute of Medicine
recommendation is that the obese woman should
gain at least 15 pounds (6 kg) during pregnancy, I
don’t think she has to gain any weight during the
pregnancy. In contrast to the small or average size
woman, the relationship between weight gain in
pregnancy and birth weight in the obese woman is
minimal. In a study done at the University of Iowa,
birth weight as the dependent variable was related
to several other variables in pregnant women
categorized by quartiles of body mass index. Total
weight gain during pregnancy was the most
important predictor of birth weight for the thinnest
quartile and was very important in the middle
quartiles. In the most obese women as indicated by
BMI, however, although the rate of weight gain in
the 3rd trimester was significantly associated with
birth weight, total weight gain was not. At least in
our population, the abundant caloric reserves and
increased blood volume and cardiac output in a
very large woman at the onset of pregnancy
apparently ensure adequate fetal nourishment. It
should also be pointed out that there is only a
modest correlation between caloric intake in
pregnancy and weight gain. Much of the weight
gain in pregnancy is fluid accumulation, which is
independent of the calories ingested. Finally, it is
likely that there is only modest association between
the recommendations that the physician makes
regarding weight gain or caloric intake and the
weight gain or caloric intake which takes place
during pregnancy. Prescribe vitamin and mineral
supplements; interdict smoking.
2. Establish a reliable EDD. Many obese women do
not ovulate regularly. Pelvic examination to
determine uterine size in early pregnancy and
fundal heights later in pregnancy are severely
hampered by obesity. Therefore, I think an ultra-
sound examination early in pregnancy should be
done in order to date the pregnancy. If diabetes or
hypertension later supervene, it is very useful to
have precise dating. Followup ultrasound exami-
nations can be done to rule out malformations
(diabetes) and intrauterine growth restriction
(hypertension). In late pregnancy, an estimated
fetal weight by ultrasound may help determine the
route of delivery, especially in women with diabe-
tes.
3. Rule out glucose intolerance early in the second
trimester, as well as at 26-28 weeks’ gestation. If
gestational diabetes is diagnosed earlier in the
pregnancy, there is more time to have blood sugars
under control and to, therefore, minimize perinatal
consequences.
4. Utilize a blood pressure cuff of appropriate size.
The bladder of the cuff should cover 80% of the
arm’s circumference in order to provide an accu-
rate reading. Too small a cuff means too high a
reading.
5. Employ third trimester fetal well being testing and
induction of labor as indicated (diabetes, hyperten-
sion, postdatism). Whether the obese gravida in the
absence of hypertension or diabetes should have
nonstress testing performed in late pregnancy is
uncertain.
6. In labor, remember that the protraction disorders in
the first stage of labor or a prolonged second stage
may indicate a relative mechanical mismatch.
Macrosomia increases the risks for maternal and
fetal trauma. Be cautious about operative vaginal
delivery.
7. If cesarean delivery is required, my personal
preference is to open the abdomen through a
vertical incision. The inferior limit of the incision
should be perpendicular to the top of the pubic
symphysis. If a large panniculus is present, most or
all of the incision may be above the umbilicus.
Mechanical means of thromboprophylaxis should
be considered. Prophylactic antibiotics are given
after cord clamping. My preference for closure of
the abdominal wall is to utilize a continuous mass
closure technique. The literature is divided as to
the value of suturing the subcutaneous tissues and
the use of subcutaneous drains. My personal
preference is to close the fat and not utilize a drain.
Weight gain recommendations in
pregnancy and the prevention of obesity
Forty years ago in the United States, the obstetric rec-
ommendation for weight gain in pregnancy was to limit
total weight gain to 25 pounds and ideally to 20 pounds.
Although it was not rational, the thought was that preec-
lampsia might be prevented. While it is true that fluid
retention in a woman with preeclampsia results in a
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large weight gain, there is no evidence that calorie re-
striction prevents preeclampsia. Nonetheless, the
obstetric focus was to attempt to seriously limit weight
gain during pregnancy. The recognition of the risks of
low birth weight and of an association between low
maternal weight gain and increased rates of low birth
weight infant delivery gave rise to the Institute of Medi-
cine recommendations listed above. I think an
unintended consequence of this is that obstetric provid-
ers began paying too little attention to excessive weight
gain during pregnancy. I know this has been a deficiency
in the prenatal care, which I provide. In one recent study,
nearly half of the women gained more than the Insti-
tute of Medicine recommendations. In the entire United
States population in 2002, 19% of parturients gained
more than 40 pounds during pregnancy.
Although the relationship between caloric intake in
pregnancy and weight gain is only modest and although
the relationship between the advice that we give and
what a patient does is also only modest, I think it is
time for us to reemphasize the importance of not gain-
ing excessive weight during pregnancy. At the time of
the first prenatal visit, the body mass index should be
calculated and depending on the weight gain category
of a patient, a recommended weight gain for the preg-
nancy should be provided. As stated above, I do not
think the obese woman needs to gain any weight dur-
ing her pregnancy. For the woman in the high initial
body mass index category, I think a weight gain of 15 to
20 pounds is appropriate. As pregnancy progresses, we
should pay attention to how much weight a woman is
gaining and should reemphasize the importance of these
weight gain limits. It is certainly typical for a woman
not to lose all the weight she gains during her first preg-
nancy and then to repeat this event on another couple
of occasions and to wind up at age 30 being 30 or 40
pounds overweight. We might during obstetric care be
able to positively affect this phenomenon.
Given the current obesity epidemic, a public health
strategy focused on preventing excessive weight gain
in pregnancy may be more beneficial overall than one
attempting to prevent inadequate weight gain. Pendu-
lums do swing.
—Frank J. Zlatnik, M.D.
Questions and Answers Regarding Progestins and
Preterm Birth Prevention
Q: What’s the buzz?
A: Progesterone, produced by the corpus luteum and
later by the placenta, has been considered important in
the maintenance of pregnancy. Progesterone suppresses
the synthesis of certain proteins associated with uter-
ine contractions and stimulates the production of an
enzyme which breaks down prostaglandins. In some
mammals progesterone levels fall prior to labor.
In the human, however, plasma progesterone levels
don’t fall prior to labor and levels are not lower in
women who deliver preterm compared with those who
deliver at term. In addition, progesterone has not been
demonstrated to be an effective tocolytic and is ineffec-
tive in the treatment of threatened abortion.
Nonetheless, a study 30 years ago suggested that proges-
terone might be effective in preventing preterm delivery
in women with histories of previous preterm births.
The recent “buzz” is due to the results of two double-
blind, placebo-controlled randomized trials of progestin
administration. In one trial (New England Journal of Medi-
cine 348:2379, 2003) 17-α-hydroxyprogesterone caproate
was compared to placebo in more than 400 women with
histories of previous preterm deliveries. Two hundred
and fifty milligrams of the drug by intramuscular injec-
tion was given weekly starting at 16-20 weeks’ gestation
and continuing until 36 weeks’ gestation. Statistically
significantly fewer women delivered preterm (less than
37 weeks) in the progesterone group as compared to
the placebo group. In addition, there were statistically
significantly fewer early preterm deliveries. Eleven per-
cent of those in the active drug group delivered under
32 weeks compared with 20% in the placebo group.
A second study utilizing progesterone vaginal sup-
positories (American Journal of Obstetrics and Gynecology
188:419, 2003) in women at high risk for preterm deliv-
ery also gave encouraging results. Progesterone vaginal
suppositories (100 mg nightly) were prescribed from
24 to 34 weeks’ gestation. Twenty-nine percent of the
women receiving the placebo suppositories delivered
preterm compared with 14% of those receiving proges-
terone. Nineteen percent of placebo recipients delivered
earlier than 34 weeks’ gestation compared with 3% of
those receiving progesterone.
Q: Who are candidates for progestin
treatment?
A: The two studies cited above involved women with
histories of previous preterm births. The drugs were
effective in preventing preterm birth in a subsequent
pregnancy. Our own practice is to utilize prophylactic
progestin therapy in a woman with a previous deliv-
ery under 35 weeks’ gestation. This delivery should
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have been the result of spontaneous labor or ruptured
membranes and not have been a birth induced for medi-
cal or obstetric complications in the absence of labor
(e.g., preeclampsia).
It is estimated that approximately 20% of early
preterm births in Iowa are accounted for by women who
have previously delivered preterm. The potential ex-
ists, therefore, for progestin therapy to have a
measurable impact on the overall rate of preterm deliv-
ery.
Q: What drugs should be given?
A: The preparations utilized were either 17-α-
hydroxyprogesterone caproate, 250 mg, given IM
weekly or progesterone vaginal suppositories, 100 mg,
given nightly. Neither of these specific preparations is
available from a national pharmaceutical company to
the best of my knowledge. We utilize the progesterone
vaginal suppositories compounded locally. Practitioners
should contact compounding pharmacies in their area
in order to see what is available.
Q: When should the drugs be
administered?
A: In the one trial, the drug was started between 16
and 20 weeks’ gestation and continued until 36 weeks.
In the second trial, the drug was administered from 24
to 34 weeks’ gestation. In our practice, we begin sup-
pository treatment just prior to mid-gestation (16-18
weeks) and continue it until 34-36 weeks’ gestation.
Q: Are there risks associated with progestin
treatment?
A: Unlikely. Progesterone is a natural substance nor-
mally found at high levels in pregnancy. Theoretically,
there could be risks associated with the vehicle in which
it is administered. Perhaps pregnancies will be abnor-
mally prolonged. Vigilance is appropriate, but I would
not withhold treatment, because of a lack of absolute
certainty regarding safety.
Q: What about using progestins in other
women at high risk for preterm delivery?
A: Other women at increased risk for preterm deliv-
ery, such as those with multiple gestations, positive fetal
fibronectin test results, short cervices on ultrasound,
previous episodes of threatened preterm labor, etc.,
might well benefit from progestin administration, but
no evidence is yet available supporting its use for these
other indications. Trials are undoubtedly underway. If
we are to practice evidence-based medicine, I think at
this point we should limit progestin use to that category
of patients in whom efficacy has been demonstrated,
namely women with histories of previous preterm de-
liveries. It is likely that information will soon be
available regarding these other possible indications.
— Frank J. Zlatnik, M.D.
Iowa Begins Newborn Screening for Cystic Fibrosis
A pilot study for the addition of cystic fibrosis (CF) to
the newborn screening panel in Iowa was recently ap-
proved by the Iowa Department of Public Health. Actual
testing began in July 2005, and the pilot phase will con-
tinue for one year. Using blood from the same card now
collected for the other components of newborn screen-
ing, immunoreactive trypsinogen will be assayed, and
the top 5% of levels will be subjected to DNA analysis,
examining for the 25 most common genetic mutations
for cystic fibrosis. During the pilot phase results will be
reported to the CF Newborn Screening Coordinator,
who will contact individual practitioners with abnor-
mal results and recommended follow up plans.
While newborn screening should identify 99% of in-
fants with CF, an occasional child will continue to be
diagnosed only when clinical manifestations suggestive
of CF develop.
Further information about the pilot for CF newborn
screening is available on the IDPH web site:
www.idph.state.ia.us/genetics/pilot_studies.asp.
Questions may also be addressed to Miles
Weinberger, MD, UIHC CF Center Director
(miles-weinberger@uiowa.edu) or to Beth Dowd, ARNP,
Iowa CF Newborn Screening Coordinator
(elizabeth-dowd@uiowa.edu) 319-356-1828.
EDITOR’S NOTE: CF carrier screening during pregnancy was consid-
ered in The Iowa Perinatal Letter in 2002 (vol. XXIII, no. 4). CF carrier
screening should be offered to Caucasians and Ashkenazi Jewish couples.
Hispanics, African-Americans, and Asians should be made aware of the
screening options. This differential recommendation, based on ethnicity, re-
flects differences in the carrier risk state before testing and the carrier risk
state after a negative test.
If both the father and the mother test positive for the CF carrier state,
diagnostic testing done at amniocentesis can establish whether or not the
fetus is affected with cystic fibrosis. Apart from termination of pregnancy,
this information might help a family make adjustments for the birth of a
child with a chronic illness. In addition, in the earlier Iowa Perinatal Let-
ter article, the point was made that numerous studies indicate a nutritional
benefit if an early diagnosis of CF is made. Since this should take place as a
result of the newborn screening program, some of the advantage of prenatal
CF carrier screening is lost for those couples who would not consider termi-
nation of pregnancy, given an affected fetus.
— Frank J. Zlatnik, M.D.
